Answers are grounded in this paper and cite their sources.
Empagliflozin is a potent and competitive SGLT-2 inhibitor with an excellent selectivity profile and the highest selectivity window of the tested SGLT-2 inhibitors over hSGLT-1. Empagliflozin represents an innovative therapeutic approach to treat diabetes.
No takes yet. Share an insight, caveat, or question.
Grempler et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: